Cereno Scientific reports first patient dosed in Phase II study in PAH with drug candidate CS1
Cereno Scientific (XSAT: CRNO B) today announced that the first patient has received their first dose of drug candidate CS1 in the Phase II study in pulmonary arterial hypertension (PAH). Prior to the dosing, the patient has undergone a screening process, implantation of the CardioMEMS HF System to monitor lung pressure during the study, and a full baseline evaluation including a 6-minute walk test, echocardiography, and MRI to enable exploration of CS1’s efficacy. Each patient will undergo a 12-week drug treatment period and a two-week follow-up period. Drug candidate CS1 aims to offer a